|
MechanismEGFR antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients With Advanced, EGFR Mutant Cancer
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
100 Clinical Results associated with Nalo Therapeutics, Inc.
0 Patents (Medical) associated with Nalo Therapeutics, Inc.
100 Deals associated with Nalo Therapeutics, Inc.
100 Translational Medicine associated with Nalo Therapeutics, Inc.